The outcome of exposure to infectious microbes or their toxins is influenced by both microbial and host genes. Some host genes encode defense mechanisms, whereas others assist pathogen functions. Genomic analyses have associated host gene mutations with altered infectious disease susceptibility, but evidence for causality is limited. Here we demonstrate that human genetic variation affecting capillary morphogenesis gene 2 (CMG2), which encodes a host membrane protein exploited by anthrax toxin as a principal receptor, dramatically alters toxin sensitivity. Lymphoblastoid cells derived from a HapMap Project cohort of 234 persons of African, European, or Asian ancestry differed in sensitivity mediated by the protective antigen (PA) moiety of anthrax toxin by more than four orders of magnitude, with 99% of the cohort showing a 250-fold range of sensitivity. We find that relative sensitivity is an inherited trait that correlates strongly with CMG2 mRNA abundance in cells of each ethnic/geographical group and in the combined population pool (P = 4 × 10
−11
). The extent of CMG2 expression in transfected murine macrophages and human lymphoblastoid cells affected anthrax toxin binding, internalization, and sensitivity. A CMG2 single-nucleotide polymorphism (SNP) occurring frequently in African and European populations independently altered toxin uptake, but was not statistically associated with altered sensitivity in HapMap cell populations. Our results reveal extensive human diversity in cell lethality dependent on PA-mediated toxin binding and uptake, and identify individual differences in CMG2 expression level as a determinant of this diversity. Testing of genomically characterized human cell populations may offer a broadly useful strategy for elucidating effects of genetic variation on infectious disease susceptibility.
lethal factor | FP59 | cellular genes exploited by pathogens | genotype T he clinical outcome of microbial infections has long been known to vary among different individuals and among ethnically and geographically diverse human populations (1) . A genetic basis for differences in infection susceptibility was first suggested by comparison of disease incidence in monozygotic vs. dizygotic twins and in members of adoptee families (2) . Later findings identified genetic traits that affect host ability to mount an immune response (3) or protect against specific pathogens (4) . Associations between human genetic variation and infectious disease incidence subsequently have been shown by linkage analysis (for reviews, see refs. 5, 6) , and by genome-wide association studies (GWASs) using haplotype maps of the human genome (7), highdensity microarray analysis (8, 9) , and DNA sequencing methods (7, (10) (11) (12) (13) . However, GWAS normally requires examination of a very large cohort to generate statistically significant associations (14) , and inherently lacks the ability to demonstrate causality between a variant and the disease phenotype.
Host variation has the potential to influence infectious disease outcome not only through genes that combat pathogens (15, 16) , but also through host genes that are needed for pathogen propagation (14, 17) or the detrimental effects of microbial toxins (18) . Among the pathogens and toxins that have been shown experimentally to exploit host genes are HIV, malaria, hepatitis, leprosy, and anthrax toxin (11) (12) (13) (19) (20) (21) (22) . Cellular genes exploited by pathogens (CGEPs) (23) may be targets for novel infectious disease therapies (24) , and genetic variation in the expression or sequence of these loci potentially may affect individual disease susceptibility or the efficacy of treatment.
Anthrax is a lethal disease caused by the toxic actions of proteins produced by the bacterium Bacillus anthracis: lethal factor (LF) and edema factor (EF) (19) . Entry of each of these proteins into cells is mediated by interaction with a third B. anthracis-generated protein, protective antigen (PA). Three host cell proteins [capillary morphogenesis gene 2 (CMG2), tumor endothelial marker 8 (TEM8), and integrin β1 (ITGB1)], which can interact with each other physically or functionally (25, 26) , can serve as receptors for the bipartite PA/LF and PA/EF toxins (26) (27) (28) . Whereas only CMG2, TEM8, and ITGB1 are known ligands of PA, 14 additional CGEPs can assist PA binding and/or internalization (26, (29) (30) (31) (32) (33) .
While investigating events that affect anthrax toxin entry, we observed that toxin sensitivity varies extensively among human lymphoblastoid cell populations derived identically from different persons. We show here that such variation in toxin sensitivity is inherited and that variation in cellular expression of CMG2 is a prominent determinant of outcome of toxin exposure. We further show that a single-nucleotide polymorphism in the protein-coding region of CMG2 independently affects toxin uptake. Our findings, which reveal the previously unsuspected magnitude of genetically determined differences in toxin sensitivity among cells from different individuals, suggest a broadly applicable approach for investigating pathogen susceptibility in diverse human populations. (7) showed a remarkable 30,000-fold difference in lethality to a toxin complex composed of PA plus FP59, a hybrid toxin that has been widely used as LF surrogate but kills cells by a different mechanism and is lethal to lymphocytes (34, 35) (Fig. 1 A and B) . The cell lines from three CEU individuals showed extraordinary resistance to toxin lethality and removing these cells from the analysis yielded a still surprisingly broad 250-fold range in LD 50 values among the remaining 99% of the population. The extraordinary toxin resistance of the three "outlier" lines was spe- cific, rather than general, as these three lines were found to show normal sensitivity to Staphylococcus aureus α-toxin. Analysis of toxin sensitivity in parent/children trios, as measured by the dose required to kill half of the cells [log(1/LD 50 )], indicated that relative sensitivity is a heritable trait (permutation P-value < 0.05) (Fig. 1C) . Interestingly, whereas the measured range in toxin lethality was similar in all four human cell populations, the European Caucasian population on average showed only about one-third the cellular sensitivity to PA-mediated toxin killing observed in other ethnic groups (P = 4 × 10 ) (excluding the three CEU highly insensitive outliers, P = 2 × 10 −11 ) (Fig. 1D) . The widespread and unimodal distribution observed for log(1/ LD 50 ) (Fig. 1B) is consistent with a polygenic inheritance model, which also is implied from evidence that multiple genes can affect anthrax toxin lethality (26) (27) (28) (29) (30) (31) (32) . Among these genes is CMG2, which encodes a type 1 transmembrane glycoprotein that recently has been shown to be the primary anthrax toxin receptor in rodents (36) . We found by RT-PCR analysis that CMG2 mRNA abundance varied over a 100-fold range in the lymphoblastoid cell populations we tested and is normally distributed (Fig. 1E) . Analysis of HapMap Project release 28 revealed no cis-acting eQTL loci that might account for such variation. Additionally, analysis in this release of genetic variation in the 17 CGEPs reported to alter anthrax toxin entry into cells (26) (27) (28) (29) (30) (31) (32) revealed that a SNP affecting an amino acid within a proline-rich region of the cytosolic tail of CMG2 (P357A; rs12647691) was among the most frequent nonsynonymous SNPs observed in the lymphoblastoid cells tested. Whereas this SNP was not associated with the observed variation in CMG2 expression in the human cell populations we tested [CEU, P = 0.98, n = 62 (excluding 3 CEU outliers P = 0.41, n = 59); YRI, P = 0.62, n = 84], interestingly, its allele frequency varied significantly among different ethnic populations. Proline, which is the ancestral amino acid found at position 357 in most placental mammals, was replaced by alanine at this location at a frequency of 34 and 36% in YRI and CEU, respectively, whereas (D) Population-specific distribution of sensitivities. CEU, YRI, JPT, and CHB denote European, Yoruba, Japanese, and Chinese Han, respectively. Three CEU outliers are excluded. For each population, the black bar represents the median log sensitivity; the box extends from the lower to the upper quartile and the whiskers extend to the most extreme data point that is no more than 1.5 times the interquartile range from the box. (E) CMG2 expression in 234 EBV-transformed B lymphocytes. Expression of CMG2 was measured by qRT-PCR and normalized for the expression of β-actin. CMG2 expression was calculated as CT ACTB − CT CMG2, where CT is the threshold cycle.
Results
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the ancestral allele persisted at 97% frequency in the HapMap Project's East Asian populations CHB and JPT (Table S1 ).
Effects of Human CMG2 Expression and P357A SNP on Anthrax Toxin
Internalization and Toxin Sensitivity. We designed experiments to determine directly whether either variation in cellular expression of CMG2 or the occurrence of the P357A SNP in the cytosolic tail of this receptor protein modulates cellular lethality to anthrax toxin. In these experiments, cultured murine macrophages expressing hCMG2 were challenged by exposure to PA plus LF; as the sequence of murine CMG2 (mCMG2) differs at multiple locations from the sequence of its human counterpart, it was practical to largely inactivate mCMG2 using an shRNA construct that does not target the human sequence. We selected a murine macrophage clone (RAW267.4-21.2) in which endogenous CMG2 mRNA had been reduced to <40% of normal, and stably transfected constructs expressing either the ancestral hCMG2 protein (357P) or its variant derivative (357A), under control of a cytomegalovirus promoter (28) , into cells of this clone. As expression of such DNA is affected by the chromosomal insertion site (37) , quantitative RT-PCR was used to identify RAW267.4-21.2 subclones that express 357A or 357P mRNA to approximately the same extent, and at an abundance that when added to residual endogenous mCMG2 abundance, yielded a total cellular CMG2 mRNA abundance that corresponds to the level determined for parental RAW264.7 cells (Fig. S1 ).
MTT assay of toxin lethality in six independently isolated stably transfected 357A or 357P clones showed that introduction of the proline-357 construct restored toxin sensitivity to almost the pre-shRNA-treatment level, whereas the 357A allele had little effect when similarly expressed ( Fig. 2A, Left) . However, higher expression of the 357A allele (clones 357A1-5 and 357A1-40) was associated with restoration of toxin lethality to approximately the level observed for the parental cell line and for transfected clones that express lesser amounts of hCMG2-357P ( Fig. 2A Center vs. 2A, Left) . A clone (357P1-0.5) that produced a lower amount of hCMG2-357P showed lesser sensitivity to the PA/LF complex. Together these findings indicate that both the SNP affecting hCMG2 amino acid residue 357 and the extent of cellular expression of the CMG2 gene govern sensitivity to anthrax lethal toxin. They further argue that these variables act independently in affecting toxin lethality.
Additional experiments elucidated the mechanisms that underlie the above observations: immunofluorescence microscopy ( Fig. 2B) and Western blotting experiments (Fig. 2C) showed that both the extent of CMG2 expression and genetic variation affecting amino acid residue 357, which is located in a hCMG2 region known to be functionally important for endocytosis of toxin (29, 30) , are determinants of PA internalization. The Western blotting experiment also showed that the amount of PA bound to the macrophage cell surface was modulated by the extent of expression of either CMG2 357A or 357P. Adventitious expression of either hCMG2 357P or 357A in human lymphoblastoid cell line GM06986, which shows low endogenous CMG2 expression and is highly resistant to killing by FP59 carried into the cells by the same protein (i.e., PA) that is the native carrier for anthrax lethal factor, generated cell populations showing an ∼2.5 × 10 3 increase in toxin lethality (Table S2 ). However, RT-PCR analysis indicated that hCMG2 expression in the 357A population was 30 times higher than expression in the hCMG2 357P population. Normalization
Association of CMG2 mRNA Abundance with Toxin Sensitivity in Human Cells. To learn whether the effects of hCMG2 expression and the P357A SNP on anthrax toxin lethality demonstrated in the experiments described above account for any of the variation in sensitivity of human lymphoblastoid cells to PA-bound FP59 seen in Fig. 1 , we tested the association of each parameter with toxin sensitivity. We detected a highly significant positive association in the overall population pool (P = 4 × 10
, n = 234, excluding CEU outliers P = 3 × 10 −9
, n = 231) and also positive association between CMG2 expression and toxin sensitivity in each of the individual populations (CEU, P = 4 × 10
, n = 62, excluding CEU outliers P = 0.003, n = 59); YRI, P = 0.002, n = 84; CHB and JPT combined, P = 8 × 10
, n = 87) (Fig. 3A) . Moreover, a linear regression model indicated that the CMG2 expression level alone accounts for 11-24% of the observed variation in sensitivity to toxin in various groups (CEU, 24%, excluding CEU outliers, 15%; YRI, 11%; East Asian populations, JPT and CHB, 17%).
We tested the possibility that differences in growth rate between cell lines may be a confounder of the association between log sensitivity and CMG2 expression. We found that including growth as a covariate has little effect on the significance of the association between log sensitivity and CMG2 expression (P = 1 × 10 −8 compared with P = 3 × 10 −9 not correcting for growth). Therefore, the association of log sensitivity with CMG2 expression is not confounded by differences in growth rate.
A statistically significant association between the P357A SNP, which affects toxin lethality in isogenic murine cells expressing the variant hCMG2 protein (Fig. 2) , with either the extent of CMG2 expression or toxin sensitivity was not detected in the limited number of lymphoblastoid cell populations we studied (Fig. 3B) . This finding suggests that the effects we have demonstrated for this SNP in cell culture experiments are modulated in genetically complex cell populations by the actions of other genes altering toxin internalization (26) (27) (28) (29) (30) (31) (32) , raising the prospect that larger cohorts may be required for detection of the effects of this SNP in such populations.
Discussion
Our findings indicate that assay of toxin sensitivity in human cell populations whose DNA sequences are known, together with experimental analysis of the effects of genetically variant CGEP cDNAs expressed in isogenic cells, offers a practical strategy for elucidating factors that underlie individual differences in cellular sensitivity to microbial toxins. The cell-based approach we used seems particularly applicable to lethal infectious diseases that occur at a low incidence in human populations. Application of this strategy has revealed an unexpectedly broad range in cellular toxin sensitivity among individuals in normal human populations and has shown the prominent influence of diversity in CMG2 expression on toxin sensitivity. If extended to multiple genes that are either exploited by or combat pathogens, the approach may facilitate development of bioassays useful in predicting outcome of exposure to pathogens or toxins.
CMG2 was identified initially during gene profiling investigations of capillary formation in vitro (38) , and inactivation of the gene results in decreased proliferation of human umbilical vein endothelial cells and diminished capillary formation (39) . Like the two other known anthrax toxin receptors located at the surface of mammalian cells (TEM8 and integrin β1) (26, 27) , CMG2 protein includes a von Willebrand domain (vWA) that binds to multiple extracellular matrix proteins, including collagen IV, laminin, and fibronectin (38) . Mutations located within the CMG2 vWA domain, the CMG2 transmembrane region, or the CMG2 cytosolic tail can result in hyaline fibromatosis syndrome (HFS), a rare and lethal autosomal recessive disease characterized by the accumulation of hyaline material in the skin and other organs (40, 41) . Although CMG2 mutations associated with HFS have been identified in the vicinity of the polymorphic locus studied here (i.e., P357A) (40, 41) point mutations affecting the cytosolic tail do not necessarily diminish CMG2 ability to function as an anthrax toxin receptor (42, 43) . Similarly, an HFS-associated mutationally truncated CMG2 protein lacking the terminal 132 amino acids of the cytosolic tail can mediate toxin endocytosis (43) . However, other HFS-causing mutations that impair CMG2 ability to bind its PA ligand decrease CMG2 folding and protein stability, and/or decrease cellular sensitivity to anthrax toxin (42) (43) (44) . Although CMG2 HFS-causing mutations in general also lead to loss of its toxin-receptor activity (42, 43) , the high frequency of the polymorphorphism we observed at amino acid 357 in European and African populations and the apparent absence of a correspondingly high HFS disease in these populations (45) suggests that this SNP does not cause HFS.
The results reported here indicate a previously unsuspected wide range of CMG2 expression and toxin sensitivity in lymphoblastoid cells derived from normal human populations. Whereas In CEU and YRI where the CMG2 SNP is present at high frequency, the association between log sensitivity and the SNP genotype under the assumption of an additive genetic model is not significant. The width of the boxplot boxes is drawn proportionally to the square root of the sample number.
multiple host cell genes have been shown to influence anthrax toxin endocytosis (26) (27) (28) (29) (30) (31) (32) or other cell functions required for toxicity (19) , the ability of CMG2 expression to explain 11-24% of overall variation in toxin sensitivity indicates that the level of expression of CMG2 is a major determinant of the outcome of toxin exposure in human cells. By contrast, the strongest single instances of genetic variation implicated thus far as determinants of height or body mass index (BMI), which also is determined by the actions of multiple genes, and similarly shows a normal distribution, explain only 0.3 and 1% of these traits, respectively (46, 47) . Efforts to identify cellular determinants of disease susceptibility by GWAS initially were based on the notion that disease phenotypes result principally from combined effects of common variations (14) . However, the surprisingly small fraction of phenotypic variation explained for complex traits by common variants identified in numerous GWASs have led some researchers to suggest instead that rare genetic variants may account for the bulk of disease-related phenotypes (14, 48) . Our study casts doubt on this notion for at least the anthrax toxin sensitivity phenotype. Whereas the polymorphism at amino acid residue 357, which is a common variant in CEU and YRI, was demonstrated to decrease toxin entry and lethality in murine cells, it was not statistically associated with altered toxin sensitivity in human cell populations. We speculate that the functional effects of the P357A variant we observed during expression of human cDNAs in mouse isogenic cells may be obscured in heterogeneous human cell populations by the combined effects of multiple other genetic variants, either common or rare.
Our data indicate that the effects of variation in the CMG2 expression level on cellular lethality upon exposure to anthrax toxin are mediated at least in part through alterations in PA binding, suggesting that the concentration of receptor at the cell surface was limiting under the experimental conditions used. Measured CMG2 expression in lymphoblastoid cells may or may not correlate with expression of this gene in other human tissues. Whether the human diversity in cellular sensitivity to the toxin extrapolates to analogous diversity in the outcome of clinical infection by B. anthracis is not known. Similarly, we do not know whether the demonstrated ability of the P357A variant to alter toxin uptake in macrophages being carried in cell culture is predictive of an effect of the SNP in infected persons or whether evolutionarily important selection by exposure to anthrax disease has influenced the strikingly different frequencies of the P357A variant observed among different populations. However, we note that sequencing of the genomes of B. anthracis strains has revealed differences in the geographical locations of genetically distinct lineages (49) : the A clade of B. anthracis is globally dispersed, whereas the B lineage was found only in Africa and Europe. As mortality rates from B. anthracis infections have been observed to be much higher in areas where B strains are endemic than in areas of A-strain prevalence (50-52), exposure to genetically different strains of B. anthracis may have exerted evolutionary pressure that has affected the incidence of the SNP in the populations we studied.
Upon binding of PA, the cytosolic tail of CMG2 undergoes a conformational change that leads to phosphorylation of cytosolic tyrosines by src-like kinases (30) . A consequence of such phosphorylation is recruitment of the adapter, β-arrestin, which induces the binding of an E3 ubiquitin ligase that ubiquitinates a lysine residue in the cytosolic tail (29, 30) . C16 carbon acyl chains are added to one or more cytosolic cysteine residues by palmitoyltransferase (53) , enabling the receptor to interact with heterotetrameric adaptor complex-dependent multimember clathrin machinery and to enter cells by clathrin-dependent endocytosis (29) . Replacement of proline-357 by alanine disrupts a segment of proline repeats in the CMG2 cytoplasmic tail, possibly affecting the ability of this proline-rich region to interact with other proteins mediating the endocytic process (54) . This notion is consistent with the observation that P357A variation affects PA internalization (Fig. 2) . Alternatively, the single alanine for proline replacement may simply affect the PA-induced conformational change that initiates the internalization of toxinreceptor complexes.
Materials and Methods
Chemicals and Reagents. PA and LF were purchased from List Biological Laboratories. FP59 was a kind gift from S. Leppla (National Institute of Allergy and Infectious Diseases /National Institutes of Health, Bethesda, MD). Retroviral vector pLEGFP-N1 (Clontech) encoding enhanced green fluorescent proteintagged human CMG2 under control of a cytomegalovirus promoter (28) was a gift from J. Young (Salk Institute for Biological Sciences, La Jolla, CA). Human CMG2 cDNA (AY233452) cloned within this vector contained proline at CMG2 amino acid 357. We replaced this proline with alanine by replacing coding nucleotide G1072 by C using site-directed mutagenesis primers: TCCACCACCACCCCCCCCTGCACCAAAAGAGGAGGAAGAAGAACCTTTGC and CTTTTGGTGCAGGGGGGGGTGGTGGTGGAGGATCCTTAATAACCACTTTG.
Cell Culture and Cell Lines. RAW264.7 mouse macrophage cells were maintained in DMEM (Invitrogen) supplemented with 10% FBS (HyClone) and 100 μg/mL penicillin and 100 μg/mL streptomycin. Human B lymphocytes were grown in Iscove's modified Dulbecco's medium (IMDM) (Invitrogen) supplemented with 15% FBS (HyClone), 100 μg/mL penicillin, and 100 μg/mL streptomycin. CMG2 knockdown experiments in mouse macrophages were done as in ref. 26 . For human CMG2 expression experiments, we transfected CMG2 knockdown RAW264.7 cells with DNA constructs using FuGENE 6 reagents according to the manufacture's protocol, followed by single clones isolation using 1 mg/mL of G418 (Gibco). In this experiment, shRNA is specific to the mouse CMG2 sequence and did not affect the expression of human CMG2. For CMG2 overexpression in human lymphocytes, infection with a retroviral-based vector expression, the 357A or 357P variant, used methods described in ref. 26 , followed by selection using 0.6 mg/mL of G418 (Gibco).
mRNA Measurements. Human CMG2 mRNA abundance was measured by realtime PCR using human CMG2-specific primers: AATTGCAGCCCTCAAGTG-TCTGTG and TCAGGATAGGTGCAGGACAAAGCA and normalized against human β-actin mRNA levels using primers AATGTGGCCGAGGACTTTGATTGC and AGGATGGCAAGGGACTTCCTGTAA in human lymphocytes or against mouse β-actin in mouse macrophages using primers CTAAGGCCAACCGT-GAAAAG and ACCAGAGGCATACAGGGACA. Mouse CMG2 mRNA abundance was measured by real-time PCR using mouse CMG2-specific primers: TAGC-TACGATGGCTGCAATCC and TCCTGCACCTGTCCTGAACAA. cDNA labeling with SYBR-green dye (Bio-Rad) was measured by the MyiQ2 detection system (Bio-Rad).
Toxin Treatment and Cell Viability Assays. Mouse macrophages were treated with toxin for 4 h and human B lymphocytes for 48 h. Determination of macrophage viability was done by MTT assay as described in refs. 31, 32, whereas lymphocyte viability was determined by Resazurin (Invitrogen) fluorescence, as described by the manufacturer. Each data point shown in Figs. 1 and 2 represents the average and SD of results from three wells. Cell viability is shown as the percentage of survivors obtained relative to treatment by PA alone (100%). LD 50 was calculated for each cell line and normalized to account for variation in toxin potency from the two different lot numbers used, as determined in five and three independent LD 50 measurements of a control cell line for the first and second lots, respectively.
Immunofluorescence Microscopy. PA protein was labeled with Alexa Fluor 647 using the protein labeling kit (A20173; Molecular Probes). We determined by MTT assay that such labeling did not affect the ability of PA/LF to kill macrophages. Fresh serum-free IMDM media was added to cells that contained 1 μg/mL PA/Alexa Fluor 647. Cells were incubated for 20 min either at 4°C for PA-binding analysis or at 37°C for determination of PA internalization.
Biochemical Assay of PA Binding and Internalization. Three million macrophage cells were exposed to 1 μg/mL of PA at 4°C for 1 h for binding assay or at 37°C for 20 min for internalization assay. Cells were then washed with PBS solution three times and lysed in RIPA buffer containing a protease inhibitor mixture (Roche). Western blot analysis was performed using mouse monoclonal anti-PA antibody PA (C3) sc-52129 (Santa Cruz Biotechnology), or mouse antiactin monoclonal antibody (Sigma-Aldrich). Chemiluminescence of bands and their relative intensities were revealed using a VersaDoc 1000 instrument (Bio-Rad).
Statistical Analysis of the Association of the CMG2 SNP and CMG2 Gene Expression with Log Sensitivity. Statistical analyses were performed in R (http://www.R-project.org/). In each population, we used a linear regression to test for the effect of the expression measured as ΔCT = CT ACTB − CT CMG2 on log sensitivity [log 10 (1/LD 50 )]. Because the results are consistent between the CHB and JPT, two East Asians populations, we pooled them to obtain a more accurate estimate of effect size in the larger combined population. Because linear regression is sensitive to outliers, we removed three outliers in log sensitivity in CEU (log sensitivity = −2.3, −2.3, and −2.6) but we note that these outliers with low sensitivity also tended to have low CMG2 expression (ΔCT = −15.2, −12.7, and −14.3). To test the effect of the SNP on log sensitivity we used an additive genetic model, where genotype is considered as zero, one, or two copies of the minor allele (corresponding to the P/P, P/A, and A/A genotypes) and each copy of the minor allele is modeled to have the same additive effect on the phenotype. We did not detect an association between the SNP genotype and log sensitivity in CEU [P value = 0.54, n = 62 (excluding three CEU outliers, P value = 0.24, n = 59)] or YRI (P value = 0.53, n = 84), and the SNP was too rare in CHB and JPT to be tested (Fig. 3B) .
The experimental data reported in this paper are tabulated in Table S3 , and genotypic data are archived in the International HapMap database (www.HapMap.org) (release 28) and in the 1000 Genomes Project (www. 1000genomes.org).
